Apellis Pharmaceuticals Excess Tax Benefit from Stock Compensation (Quarterly) Analysis

Apellis Pharmaceuticals, Inc. (APLS)

21.66 +0.71 (+3.39%) USD | NASDAQ | Jan 22, 10:43

View Excess Tax Benefit from Stock Compensation (Quarterly) for APLS.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View Excess Tax Benefit from Stock Compensation (Quarterly) Chart

Start Trial

View Historical Data

Start Trial

View Excess Tax Benefit from Stock Compensation (Quarterly) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View Excess Tax Benefit from Stock Compensation (Quarterly) Benchmarks

Start Trial

Amicus Therapeutics, Inc.	--
Alnylam Pharmaceuticals, Inc.	--
Ionis Pharmaceuticals, Inc.	--
Fortress Biotech, Inc.	--
Sarepta Therapeutics, Inc.	--